3-D Matrix Ltd (7777):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:3-D Matrix Ltd (7777) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11481
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
3-D Matrix Ltd (3-D Matrix) is a regenerative medicine company that focuses at commercializing its self-assembling peptide technology. It develops medical products by applying this technology under a license granted by Massachusetts Institute of Technology (MIT). The technology finds applications in the field of surgical and medical regenerative medicine, cell therapy and drug discovery. 3-D Matrix’s lead product, PuraMatrix caters to periodontal bone regeneration. The company has several collaborative agreements with academic research institutions, enterprises and medical institutions. The company operates across the US, France, the Netherlands, China and Singapore. 3-D Matrix is headquartered in Chiyoda-ku, Tokyo, Japan.

3-D Matrix Ltd (7777) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-D Matrix Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3-D Matrix Ltd, Medical Devices Deals, 2012 to YTD 2018 9
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Daewoong Pharma Enters into Licensing Agreement with 3-D Matrix Asia 11
Fuso Pharma Enters Into Licensing Agreement With 3-D Matrix For TDM-641 12
Equity Offering 13
3-D Matrix Raises USD7.8 Million in Private Placement of Shares 13
3-D Matrix Ltd – Key Competitors 14
3-D Matrix Ltd – Key Employees 15
3-D Matrix Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-D Matrix Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-D Matrix Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
3-D Matrix Ltd, Medical Devices Deals, 2012 to YTD 2018 9
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Daewoong Pharma Enters into Licensing Agreement with 3-D Matrix Asia 11
Fuso Pharma Enters Into Licensing Agreement With 3-D Matrix For TDM-641 12
3-D Matrix Raises USD7.8 Million in Private Placement of Shares 13
3-D Matrix Ltd, Key Competitors 14
3-D Matrix Ltd, Key Employees 15
3-D Matrix Ltd, Subsidiaries 16

List of Figures
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3-D Matrix Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3-D Matrix Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[3-D Matrix Ltd (7777):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cerner Corp (CERN):医療機器:M&Aディール及び事業提携情報
    Summary Cerner Corp (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; …
  • Ecrins Therapeutics SAS-製薬・医療分野:企業M&A・提携分析
    Summary Ecrins Therapeutics SAS (Ecrins) is a biotechnology company that discovers and develops small molecule drug candidates against several oncology indications in humans and domestic animals. The company provides products such as native and labeled tubulin, tubulin polymerization kit and monoclo …
  • Marina Portoroz dd:企業の戦略・SWOT・財務分析
    Marina Portoroz dd - Strategy, SWOT and Corporate Finance Report Summary Marina Portoroz dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bausch & Lomb Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bausch & Lomb Inc (Bausch & Lomb), a subsidiary of Valeant Pharmaceuticals International Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It offers over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, …
  • Sino-Ocean Land Holdings Limited:戦略・SWOT・企業財務分析
    Sino-Ocean Land Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Sino-Ocean Land Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • PACCAR Inc (PCAR):企業の財務・戦略的SWOT分析
    PACCAR Inc (PCAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mitsubishi Materials Corp:企業の戦略・SWOT・財務情報
    Mitsubishi Materials Corp - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Materials Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Voya Financial, Inc.:企業の戦略・SWOT・財務情報
    Voya Financial, Inc. - Strategy, SWOT and Corporate Finance Report Summary Voya Financial, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • United Therapeutics Corporation:企業の戦略・SWOT・財務情報
    United Therapeutics Corporation - Strategy, SWOT and Corporate Finance Report Summary United Therapeutics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aeras Global TB Vaccine Foundation Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines. The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinica …
  • Grupo Aval Acciones Y Valores Sa:企業の戦略・SWOT・財務分析
    Grupo Aval Acciones Y Valores Sa - Strategy, SWOT and Corporate Finance Report Summary Grupo Aval Acciones Y Valores Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • BTA Bank JSC:企業の戦略・SWOT・財務情報
    BTA Bank JSC - Strategy, SWOT and Corporate Finance Report Summary BTA Bank JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Deutsche Borse AG:企業の戦略・SWOT・財務情報
    Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Borse AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Cosmo Bio Co Ltd (3386):企業の財務・戦略的SWOT分析
    Summary Cosmo Bio Co Ltd (Cosmo Bio) operates as a medical device company that offers markets research reagents and research instruments. The company’s product categories include antibodies, assay and detection, cells and cell culture, bioactive substances, protein engineering, separation and purifi …
  • Bertelsmann SE & Co. KGaA:企業の戦略・SWOT・財務分析
    Bertelsmann SE & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary Bertelsmann SE & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Ebiquity plc (EBQ):企業の財務・戦略的SWOT分析
    Summary Ebiquity plc (Ebiquity) is a marketing and media consultancy service provider. The company’s services include marketing performance optimization services, media value measurement and market intelligence. Its business areas comprise data analytics and advanced analytics. Ebiquity’s data analy …
  • Compumedics Ltd (CMP):企業の財務・戦略的SWOT分析
    Summary Compumedics Ltd (Compumedics) is a medical device company that develops and commercializes computer-based medical products. The company designs, develops and commercializes computer aided medical diagnostic systems. It provides product categories such as sleep diagnostics, neurology diagnost …
  • Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer an …
  • Just Dial Ltd:企業の戦略・SWOT・財務情報
    Just Dial Ltd - Strategy, SWOT and Corporate Finance Report Summary Just Dial Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Kewpie Corporation:戦略・SWOT・企業財務分析
    Kewpie Corporation - Strategy, SWOT and Corporate Finance Report Summary Kewpie Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆